Blogs
Read article Why Volumetric Absorptive Microsampling (VAMS) Is Transforming Whole Blood Bioanalysis

As drug development programs continue to expand into more complex therapeutic modalities and patient-centric clinical trial designs, bioanalytical laboratories are under increasing pressure to generate high-quality data from smaller, less invasive samples. Volumetric absorptive microsampling (VAMS) has emerged as a promising solution, offering a practical alternative to traditional blood…

KC-Building_KCASBio Videos
Watch Video Kansas City Lab Tour

Full laboratory tour of the KCAS Bio location in Kansas City, KS USA. Interested in speaking with one of our experts? Fill out the form below to connect with a KCAS Bio scientist.

LYON_Building_KCASBio Videos
Watch Video Lyon, France Lab Tour

Full laboratory tour of the KCAS Bio location in Kansas City, KS USA. Interested in speaking with one of our experts? Fill out the form below to connect with a KCAS Bio scientist.

Functional assays in drug development_KCASBio Blogs
Read article Functional Assays in Drug Development: A Complete Guide to Evaluating Biological Activity

What are functional assays? Understanding the interactions between drugs and biological systems is critical for the success of a new drug. One key tool in this process is functional assays. Functional assays in drug development are customized assays that evaluate the impact of drugs on the functionality of cells.

Continuity without Compromise_KCASBio Blogs
Read article Continuity Without Compromise: How KCAS Bio Delivers End‑to‑End Bioanalytical Support Across Modalities

In today’s fast-moving drug development landscape, bioanalytical continuity and end-to-end support aren’t just conveniences, they’re competitive advantages. Sponsors navigating complex modalities like gene therapies, ADCs, oligonucleotides, and biologics need a partner who can keep pace with aggressive timelines, shifting priorities, and evolving regulatory expectations. Why Continuity Matters in…

Biomarker Webinar webinars
Read article Biomarkers Roundtable: Practical Insights for LBA and Molecular Assays

Biomarkers can move a program forward fast. Or slow it down with rework. Biomarkers shape decisions from discovery through late-stage clinical trials. But the wrong assay plan can waste time, budget and samples. In this KCAS Bio roundtable, we share practical ways to align context of use,…

KCAS-blog-thumb_2026-02-RO Assay and TE Blogs
Read article From Preclinical to Clinical: Tracking Target Binding in Solid Tumor Therapy

At KCAS Bio, we supported a therapeutic monoclonal antibody for advanced solid tumors from non-human primate (NHP) toxicology through first-in-human (FIH) dose escalation into phase 2 expansion. This project combined receptor occupancy assays (ROA) by flow cytometry for cell-surface binding on monocytes, immunophenotyping (IPT) for activation markers,…

From LBA to LC-MS/MS: Solving the PK/PD Disconnect in Biotherapeutic Stability Blogs
Read article From LBA to LC-MS/MS: Solving the PK/PD Disconnect in Biotherapeutic Stability

Developing a robust Pharmacokinetic (PK) assay for biotherapeutics often presents unforeseen biological hurdles. Occasionally, a traditional Ligand Binding Assay (LBA) may yield inconsistent data. In this particular case, the LBA assay was not reliably detecting drug in the matrix, potentially indicating some matrix stability issue during method development. In…

Ligand Binding Assays: Technologies & Applications Blogs
Read article Ligand Binding Assay Technologies for Bioanalytical Drug Development

What Are Ligand Binding Assays (LBAs)? Ligand binding assays (LBAs) have been our core activity for decades. LBAs are commonly used to measure interactions between two proteins, a ligand and its receptor, a monoclonal antibody (mAb) and its target, or a biologic and Anti-Drug Antibodies (ADA). What Are…

Behind The Scenes of Method Development in Bioanalysis_KCASBio Blogs
Read article Behind The Scenes of Method Development in Bioanalysis

In a bioanalytical CRO, method development is a critical step to ensure reliable and meaningful data that meets the client’s requirements. At our KCAS Bio – Lyon site, our method development team specializes in designing and optimizing ligand-binding assay (LBA) methods tailored to our clients’ specific objectives.

THE ROLE OF IMMUNOGENICITY IN DISEASE & THERAPY RESPONSE: A COMPARATIVE ANALYSIS OF ASSESSMENT METHODS Blogs
Read article Immunogenicity Assessment Methods: Comparing Flow Cytometry, ELISpot & Biomarker Assays

What is Immunogenicity Assessment? Immunogenicity refers to the ability of a substance, such as a New Biological Entity (NBE) or a vaccine, to provoke an immune response when administered in the body. The recognition of the substance as foreign triggers an immune response, which involves the production of antibodies and…

immunogenicity-bioassay-summit-KCASBio October 7 - October 10

KCAS Bio will be participating in the Immunogenicity & Bioassay Summit 2025, taking place October 7-10 in Alexandria, VA. This annual summit, hosted by the Cambridge Healthtech Institute, brings together leaders in immunogenicity assessment, bioassay development, and translational science to explore emerging strategies in drug development. With focused…